Analyst picks & changes
Analyst picks & changes
| Company | Bank | Analyst | Coverage | Opinion | Wk chg | 4/20 cls |
| Genzyme (GENZ) | Fortis | Geraldine O'Keeffe | New | Buy | 1% | $63.22 |
| O'Keeffe set a $74 target. She noted GENZ expects results this year from Phase III trials of tolevamer to treat Clostridium difficile-associated diarrhea and Mozobil to treat multiple myeloma and | ||||||
